NeuroSense Therapeutics Ltd. Ordinary Shares — Quarterly Financial Statements (NASDAQ:NRSN) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Market Capitalization 23.77 M
Employee 15
Founded 2017
CEO N/A
Website www.neurosense-tx.com
Headquarter Israel
FIGI UNKNOWN
Industry Biotechnologies

Total debt

Free cash flow

Cash & equivalents

23.77 M Market capitalization

Nouvelles

Roth/MKM initie la couverture de NeuroSense avec un achat

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential

Le titre de Neurosense Therapeutics grimpe après l’obtention d’un brevet australien pour PrimeC

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

L’action de Neurosense grimpe suite au profil d’innocuité favorable de son médicament contre Alzheimer

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)